If you have patience, this healthcare stock is nice to hold long term. In 2024, revenue rose 13% year-over-year to $371.3 ...

The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS ...